JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266968

Human RARRES3 (TIG3) knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PLAAT4 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 3 and 5 bp deletion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human RARRES3 (TIG3) knockout A549 cell line (AB266968)
  • Sanger seq

Unknown

Sanger Sequencing - Human RARRES3 (TIG3) knockout A549 cell line (AB266968)

Allele-2 : 2 bp deletion in exon 3.

Sanger Sequencing - Human RARRES3 (TIG3) knockout A549 cell line (AB266968)
  • Sanger seq

Unknown

Sanger Sequencing - Human RARRES3 (TIG3) knockout A549 cell line (AB266968)

Allele-1 : 5 bp deletion in exon3

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 3 and 5 bp deletion in exon 3

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266968-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266968 Human RARRES3 (TIG3) knockout A549 cell line", "number":"AB266968-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB266968-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266968-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB266968-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266968 Human RARRES3 (TIG3) knockout A549 cell line", "number":"AB266968-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266968-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266968 Human RARRES3 (TIG3) knockout A549 cell line", "number":"AB266968-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266968-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266968 Human RARRES3 (TIG3) knockout A549 cell line", "number":"AB266968-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PLAAT4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TIG3 also known as tazarotene-induced gene 3 or retinoic acid receptor responder 3 is a protein with a mass of approximately 21 kDa. It plays a role in cellular processes such as differentiation and apoptosis. This protein is expressed mainly in epithelial tissues like the skin where it responds to retinoids. Its expression is often upregulated by the topical application of tazarotene a retinoid treatment commonly used in dermatology.
Biological function summary

TIG3 regulates cellular differentiation and promotes apoptosis. It does not form part of a larger complex but interacts with several key proteins in cell cycle control. TIG3 has an important role in maintaining the balance between cell proliferation and apoptosis particularly in keratinocytes. This regulatory action is important in skin health and response to external signals which might include pharmaceutical agents like retinoids.

Pathways

TIG3 acts primarily in the retinoic acid signaling pathway. This pathway involves its interaction with retinoic acid receptors such as RAR and RXR which regulate gene expression. These interactions influence the transcriptional activity of genes controlling cell differentiation and growth arrest. Additionally TIG3 has a link with the apoptosis pathway where it mediates the expression of proteins like p53 a well-known tumor suppressor that can induce cell cycle arrest and apoptosis.

TIG3 plays a significant role in skin conditions such as psoriasis and skin cancer. Its ability to induce apoptosis in keratinocytes makes it a target for treatments aiming to normalize skin cell turnover. In psoriasis aberrant regulation of TIG3 expression can lead to excessive proliferation of skin cells. Moreover its interaction with p53 highlights its potential role in skin cancer where dysregulation of apoptotic pathways is a common event. Understanding TIG3's function and regulation can assist in developing therapies for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com